KZR - ケザ―・ライフ・サイエンシズ (Kezar Life Sciences Inc.) ケザ―・ライフ・サイエンシズ

 KZRのチャート


 KZRの企業情報

symbol KZR
会社名 Kezar Life Sciences Inc (ケザ―・ライフ・サイエンシズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Kezar Life Sciences Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small molecule therapeutics to treat autoimmune disorders cancer and malignant diseases. Its therapies target protein homeostasis. Its lead development program is KZR-616. KZR-616 is a selective small molecule inhibitor of the immunoproteasome. Its second program focuses on small-molecule modulators of the protein secretion pathway. Its protein secretion program is focused on the areas of oncology inflammation and immune-oncology.   ケザ―・ライフ・サイエンシズは米国のバイオ医薬品企業。臨床段階で、がんおよび自己免疫疾患において満たされていない分野の新規小分子治療薬の発見・開発に従事する。同社のリ―ド製品候補であるKZRR-616は、狼そう病およびル―プス腎炎の治療に使用される。本社所在地はカリフォルニア州サウス・サンフランシスコ。   Based in South San Francisco, Kezar Life Sciences is combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. KZR-616, a first-in-class selective immunoproteasome inhibitor, is being evaluated in severe and underserved autoimmune diseases. Additionally, KZR-261, the first clinical candidate for the treatment of cancer from the company's protein secretion program targeting the Sec61 translocon, is undergoing IND-enabling activities.
本社所在地 4000 Shoreline Court Suite 300 South San Francisco CA 94080 USA
代表者氏名 John Fowler ジョン・ファウラー
代表者役職名 Chief Executive Officer Co-Founder
電話番号 +1 650-822-5600
設立年月日 42036
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 20人
url www.kezarlifesciences.com
nasdaq_url https://www.nasdaq.com/symbol/kzr
adr_tso
EBITDA EBITDA(百万ドル) -16.27800
終値(lastsale) 21.96
時価総額(marketcap) 419616533.16
時価総額 時価総額(百万ドル) 487.25960
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 368.87460
当期純利益 当期純利益(百万ドル) -16.10200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Kezar Life Sciences Inc revenues was not reported. Net loss increased from $4.1M to $11.7M. Higher net loss reflects Research and development - Balancing val increase from $3.2M to $8.2M (expense) General and administrative - Balancing v increase from $823K to $2.7M (expense) Stock-Based Compensation Expense increase from $37K to $617K (expense).

 KZRのテクニカル分析


 KZRのニュース

   Kezar Life Sciences Appoints Gitanjali Jain as Vice President, Investor Relations and External Affairs  2021/10/05 20:01:00 Business Wire
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated
   The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study  2021/09/16 11:48:49 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC ) Bicycle Therapeutics plc (NASDAQ: BCYC ) Bio-Techne Corporation (NASDAQ: TECH ) Cytek Biosciences, Inc. (NASDAQ: CTKB ) Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA ) IVERIC bio, Inc. (NASDAQ: ISEE ) Kezar Life Sciences, Inc. (NASDAQ: KZR ) Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT ) Repligen Corporation (NASDAQ: RGEN ) Vera Therapeutics, Inc. (NASDAQ: VERA ) Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 15) 4D pharma plc (NASDAQ: LBPS ) (announced biomarker analyses from two studies of MRx0518 in solid tumor settings) Achilles Therapeutics plc (NASDAQ: ACHL ) Acutus Medical, Inc. (NASDAQ: AFIB ) Aditxt, Inc. (NASDAQ: ADTX ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Ardelyx, Inc. (NASDAQ: ARDX ) AzurRx BioPharma, Inc. (NASDAQ: AZRX ) CVRx, Inc. (NASDAQ: CVRX ) Dermata Therapeutics, Inc.
   Kezar Life Sciences (KZR) Corporate Overview  2021/09/10 20:03:15 Seeking Alpha
   The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi''s Pemphigus Trial Disappointment, Humanigen''s COVID-19 Drug Denied Emergency Use Authorization  2021/09/09 12:17:06 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE: ABT ) Candel Therapeutics, Inc. (NASDAQ: CADL ) (announced its quarterly results) Cardiol Therapeutics Inc. (NASDAQ: CRDL ) Catalent, Inc. (NASDAQ: CTLT ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) DexCom, Inc. (NASDAQ: DXCM ) Edwards Lifesciences Corporation (NYSE: EW ) ICU Medical, Inc. (NASDAQ: ICUI ) (announced a deal to buy Smiths Medical division for $2.35 billion in cash) IDEAYA Biosciences, Inc. (NASDAQ: IDYA ) Insulet Corporation (NASDAQ: PODD ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Kadmon Holdings, Inc. (NASDAQ: KDMN ) - announced a deal to be bought by Sanofi (NASDAQ: SNY ) Kezar Life Sciences, Inc. (NASDAQ: KZR ) Medtronic plc (NYSE: MDT ) MiMedx Group, Inc. (NASDAQ: MDXG ) Nuvalent, Inc. (NASDAQ: NUVL ) (announced its second-quarter results) Quest Diagnostics Incorporated (NYSE: DGX ) ResMed Inc.
   The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself  2021/09/03 11:31:12 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Abbott Laboratories (NYSE: ABT ) (announced acquisition of medical device company Walk Vascular) Adagio Therapeutics, Inc. (NASDAQ: ADGI ) (IPOed Aug. 6) Axonics, Inc. (NASDAQ: AXNX ) Bicycle Therapeutics plc (NASDAQ: BCYC ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Bio-Techne Corporation (NASDAQ: TECH ) Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN ) Catalent, Inc. (NASDAQ: CTLT ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE ) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) (announced COO appointment) Cryo-Cell International, Inc. (NASDAQ: CCEL ) (announced uplisting to Nasdaq on Tuesday) DexCom, Inc. (NASDAQ: DXCM ) Edwards Lifesciences Corporation (NYSE: EW ) Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA ) Erasca, Inc. (NASDAQ: ERAS ) Genmab A/S (NASDAQ: GMAB ) Globus Medical, Inc. (NYSE: GMED ) Intuitive Surgical, Inc.
   The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself  2021/09/03 11:31:12 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Abbott Laboratories (NYSE: ABT ) (announced acquisition of medical device company Walk Vascular) Adagio Therapeutics, Inc. (NASDAQ: ADGI ) (IPOed Aug. 6) Axonics, Inc. (NASDAQ: AXNX ) Bicycle Therapeutics plc (NASDAQ: BCYC ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Bio-Techne Corporation (NASDAQ: TECH ) Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN ) Catalent, Inc. (NASDAQ: CTLT ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE ) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) (announced COO appointment) Cryo-Cell International, Inc. (NASDAQ: CCEL ) (announced uplisting to Nasdaq on Tuesday) DexCom, Inc. (NASDAQ: DXCM ) Edwards Lifesciences Corporation (NYSE: EW ) Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA ) Erasca, Inc. (NASDAQ: ERAS ) Genmab A/S (NASDAQ: GMAB ) Globus Medical, Inc. (NYSE: GMED ) Intuitive Surgical, Inc.
   Kezar Life Sciences to Participate in Two Upcoming Investor Conferences  2021/09/02 11:00:00 Kezar Life Sciences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced members of the executive team will participate in the following upcoming virtual investor conferences: Wells Fargo Virtual Healthcare Conference Thursday, September 9, 2021, 4:00 PM ET Presenter: John Fowler, Chief Executive Officer, and Noreen Roth Henig, M.D., Chief Medical Officer H. C. Wainwright 23rd Annual Global Investment Conference Monday, September 13, 2021, 7:00 AM ET Presenter: John Fowler, Chief Executive Officer A webcast of both presentations may be accessed at the Events & Presentations section of Kezars website at https://www.kezarlifesciences.com/investors/news-events/ir-calendar . Kezar Life Sciences will maintain an archived replay of the webcasts on its website for 90 days after the conferences. About Kezar Life Sciences Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders.
   The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical  2021/08/31 12:05:06 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN ) Alkermes plc (NASDAQ: ALKS ) Axonics, Inc. (NASDAQ: AXNX ) Bio-Techne Corporation (NASDAQ: TECH ) BioLife Solutions, Inc. (NASDAQ: BLFS ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE ) Clearside Biomedical, Inc. (NASDAQ: CLSD ) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) Cytokinetics, Incorporated (NASDAQ: CYTK ) Dermata Therapeutics, Inc. (NASDAQ: DRMA ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Eliem Therapeutics, Inc. (NASDAQ: ELYM ) (IPOed Aug. 10) Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA ) IVERIC bio, Inc. (NASDAQ: ISEE ) Kezar Life Sciences, Inc. (NASDAQ: KZR ) Merit Medical Systems, Inc. (NASDAQ: MMSI ) MiMedx Group, Inc. (NASDAQ: MDXG ) PDS Biotechnology Corporation (NASDAQ: PDSB ) Pieris Pharmaceuticals, Inc.
   Kezar Life Sciences completes enrollment in mid-stage polymyositis trial  2021/08/23 11:32:19 Seeking Alpha
   Kezar Life Sciences Announces Completion of Enrollment of Its Phase 2 PRESIDIO Clinical Trial of KZR-616 in Polymyositis and Dermatomyositis  2021/08/23 11:01:00 Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that PRESIDIO, its Phase 2 clinical trial to evaluate the safety and efficacy of KZR-616 for the treatment of polymyositis (PM) and dermatomyositis (DM) completed the target enrollment of 24 subjects. PRESIDIO is a Phase 2 randomized, placebo-controlled, crosso
   Kezar Life Sciences (NASDAQ:KZR) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS  2021/03/13 15:34:41 Transcript Daily
Kezar Life Sciences (NASDAQ:KZR) posted its quarterly earnings data on Thursday. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01, MarketWatch Earnings reports. Shares of Kezar Life Sciences stock opened at $6.80 on Friday. The firm has a fifty day moving average of $5.76 and a […]
   Kezar Life Sciences Reports Fourth Quarter and Year End 2020 Financial Results and Provides Business Updates  2021/03/11 21:01:00 Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its fourth quarter and year end 2020 financial results and corporate highlights. “Despite unprecedented circumstances, 2020 was a year of significant corporate and clinical accomplishments, thanks to the excellent execution by the Kezar team,” said John Fowler,
   Kezar Life Sciences to Present at H.C. Wainwright Virtual BioConnect Conference  2021/01/07 21:02:00 Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Chief Executive Officer, John Fowler, will present a corporate overview at the H.C. Wainwright Virtual BioConnect Conference, being held on January 11-14, 2021. The presentation will be available on Monday, January 11, 2021 at 6:00am EST and may be accessed
   Kezar Life Sciences Added to the Nasdaq Biotechnology Index  2020/12/14 21:01:00 Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it has been added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to market open on Monday, December 21, 2020. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®
   Kezar Life Sciences Reports Third-Quarter 2020 Financial Results and Provides Business Updates  2020/11/05 21:01:00 Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its third-quarter 2020 financial results and corporate highlights. “The third quarter of 2020 saw continued momentum for Kezar, punctuated by the U.S. FDA granting Orphan Drug Designations for our lead candidate KZR-616 for the treatment of polymyositis and der

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ケザ―・ライフ・サイエンシズ KZR Kezar Life Sciences Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)